Eric Whitaker - 10X GENOMICS General Counsel
| 1KJ Stock | EUR 14.11 0.49 3.36% |
Insider
Eric Whitaker is General Counsel of 10X GENOMICS DL since 2017.
| Age | 52 |
| Tenure | 7 years |
| Phone | 925 401 7300 |
| Web | http://www.10xgenomics.com |
10X GENOMICS Management Efficiency
The company has return on total asset (ROA) of (0.0892) % which means that it has lost $0.0892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2122) %, meaning that it generated substantial loss on money invested by shareholders. 10X GENOMICS's management efficiency ratios could be used to measure how well 10X GENOMICS manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| BSc LLB | Nufarm Limited | N/A | |
| Hidehiko Matsui | Hitachi Construction Machinery | 62 | |
| Kjersti Wiklund | TRAINLINE PLC LS | 56 | |
| Neil Murrin | TRAINLINE PLC LS | N/A | |
| Brian McBride | TRAINLINE PLC LS | 64 | |
| AMP AICD | Nufarm Limited | 64 | |
| Jennifer Duvalier | TRAINLINE PLC LS | N/A | |
| Yusuke Araki | Hitachi Construction Machinery | N/A | |
| CMA CPA | North American Construction | N/A | |
| Rico Christensen | Nufarm Limited | 53 | |
| Seimei Toonishi | Hitachi Construction Machinery | 61 | |
| Rachel Scully | Nufarm Limited | N/A | |
| Yasushi Ochiai | Hitachi Construction Machinery | 67 | |
| Paul Townsend | Nufarm Limited | 57 | |
| Masafumi Senzaki | Hitachi Construction Machinery | 58 | |
| Kazunori Nakamura | Hitachi Construction Machinery | 60 | |
| Duncan TattonBrown | TRAINLINE PLC LS | 54 | |
| Keiichiro Shiojima | Hitachi Construction Machinery | 58 | |
| Hideshi Fukumoto | Hitachi Construction Machinery | 66 | |
| John Holding | Nufarm Limited | N/A | |
| Seishi Toyoshima | Hitachi Construction Machinery | 63 | |
Management Performance
| Return On Equity | -0.21 | |||
| Return On Asset | -0.0892 |
10X GENOMICS DL Leadership Team
Elected by the shareholders, the 10X GENOMICS's board of directors comprises two types of representatives: 10X GENOMICS inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 10X. The board's role is to monitor 10X GENOMICS's management team and ensure that shareholders' interests are well served. 10X GENOMICS's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 10X GENOMICS's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mathai Mammen, Independent Director | ||
| Bradford Crutchfield, Chief Commercial Officer | ||
| Jean Philibert, Chief People Officer | ||
| Benjamin Hindson, President Co-Founder, Chief Scientific Officer, Director | ||
| Brad Crutchfield, Chief Commercial Officer | ||
| Justin McAnear, Chief Financial Officer | ||
| Shehnaaz Suliman, Independent Director | ||
| Eric Whitaker, General Counsel | ||
| Serge Saxonov, Chief Executive Officer, Co-Founder, Director | ||
| Sridhar Kosaraju, Independent Director | ||
| Bryan Roberts, Independent Director | ||
| John Stuelpnagel, Independent Chairman of the Board | ||
| Kimberly Popovits, Independent Director |
10X Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 10X GENOMICS a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.0892 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.28) % | |||
| Shares Outstanding | 95.6 M | |||
| Shares Owned By Insiders | 2.60 % | |||
| Shares Owned By Institutions | 99.56 % | |||
| Revenue | 503.71 M | |||
| Gross Profit | 416.4 M | |||
| EBITDA | (117.15 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in 10X Stock
10X GENOMICS financial ratios help investors to determine whether 10X Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 10X with respect to the benefits of owning 10X GENOMICS security.